Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,346 result(s) found. Displaying page 1,380 of 2,218.
    «« First « Previous 1376  1377  1378  1379  1380  1381  1382  1383  1384  Next» Last»»
    EudraCT Number: 2015-002974-20 Sponsor Protocol Number: 1237.28 Start Date*: 2016-08-04
    Sponsor Name:SCS Boehringer Ingelheim Comm. V
    Full Title: A randomised, double-blind, cross-over study to evaluate the effect of 6 weeks treatment of orally inhaled tiotropium + olodaterol fixed dose combination (5/5 µg) compared with tiotropium (5 µg),...
    Medical condition: Patients with moderate to severe Chronic Obstructive Pulmonary Disease according to the GOLD guidelines.
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004855 10009026 Chronic obstructive airways disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-001932-38 Sponsor Protocol Number: FLU-v003 Start Date*: 2016-07-22
    Sponsor Name:PepTcell Limited (trading as SEEK)
    Full Title: A randomised, double-blind, placebo-controlled, single-centre phase IIb trial as part of the EU-funded UNISEC project to assess the immunogenicity and safety of different formulations and dosing re...
    Medical condition: Influenza A and/or B
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-002475-29 Sponsor Protocol Number: GS-US-218-1502 Start Date*: 2015-02-10
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT...
    Medical condition: Respiratory Syncytial Virus (RSV) Infection of the lower respiratory tract.
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10039247 RSV infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-002987-17 Sponsor Protocol Number: ALN-TTR02-004 Start Date*: 2013-11-25
    Sponsor Name:Alnylam Pharmaceuticals, Inc
    Full Title: APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneu...
    Medical condition: Transthyretin mediated amyloidosis (ATTR)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10007541 - Cardiac disorders 10007509 Cardiac amyloidosis PT
    19.0 10010331 - Congenital, familial and genetic disorders 10019889 Hereditary neuropathic amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) ES (Completed) PT (Completed) IT (Completed) DE (Completed) NL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-003002-17 Sponsor Protocol Number: 63623872FLZ2002 Start Date*: 2015-11-17
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult and Elderly H...
    Medical condition: Influenza A virus infection
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10022002 Influenza A virus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) BE (Completed) DE (Completed) NL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-004455-36 Sponsor Protocol Number: NP28673 Start Date*: 2013-04-11
    Sponsor Name:F.Hoffmann-La Roche Ltd
    Full Title: AN OPEN-LABEL, NON-RANDOMIZED, MULTICENTER PHASE I/II TRIAL OF RO5424802 GIVEN ORALLY TO NON - SMALL CELL LUNG CANCER PATIENTS WHO HAVE ALK MUTATION AND FAILED CRIZOTINIB TREATMENT
    Medical condition: ALK-mutated Non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) DE (Completed) IT (Completed) ES (Completed) NL (Completed) BE (Completed) FR (Completed) DK (Completed) LU (Completed)
    Trial results: View results
    EudraCT Number: 2014-000920-26 Sponsor Protocol Number: KCP-330-008 Start Date*: 2014-09-08
    Sponsor Name:Karyopharm Therapeutics, Inc.
    Full Title: A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) versus Specified Physician’s Choice in Patients ≥ 60 Years Old with Relapsed/Refracto...
    Medical condition: Acute Myeloid Leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) NL (Completed) GB (Completed) DK (Prematurely Ended) BE (Completed) HU (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-002003-28 Sponsor Protocol Number: 53718678RSV1005 Start Date*: 2015-11-04
    Sponsor Name:Janssen Sciences Ireland UC
    Full Title: A Phase 1b, randomized, partially double-blind, placebo-controlled study to assess the pharmacokinetics, safety, and tolerability of multiple doses of orally administered JNJ-53718678 in infants ho...
    Medical condition: Respiratory Syncytial Virus
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10038717 Respiratory syncytial viral infections HLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed) BE (Completed) ES (Prematurely Ended) NL (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-003545-18 Sponsor Protocol Number: C14012 Start Date*: 2012-04-24
    Sponsor Name:Millennium Pharmaceuticals, Inc
    Full Title: A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripher...
    Medical condition: Relapsed or Refractory Peripheral T-Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034629 Peripheral T-cell lymphoma unspecified stage III PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034628 Peripheral T-cell lymphoma unspecified stage II PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034627 Peripheral T-cell lymphoma unspecified stage I PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034626 Peripheral T-cell lymphoma unspecified refractory PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034625 Peripheral T-cell lymphoma unspecified recurrent PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034630 Peripheral T-cell lymphoma unspecified stage IV PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034623 Peripheral T-cell lymphoma unspecified PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) PT (Completed) DE (Completed) HU (Completed) AT (Completed) GB (Completed) ES (Completed) DK (Completed) NL (Completed) BG (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-016839-35 Sponsor Protocol Number: PX-171-009 Start Date*: 2010-09-07
    Sponsor Name:Onyx Therapeutics, Inc.
    Full Title: Estudio en fase 3 multicéntrico y aleatorizado de comparación de carfilzomib, lenalidomida y dexametasona (CRd) con lenalidomida y dexametasona (Rd) en pacientes con mieloma múltiple recidivado. A...
    Medical condition: Mieloma múltiple. Multiple myeloma.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed) BE (Completed) NL (Completed) CZ (Completed) DE (Completed) AT (Completed) BG (Completed) FR (Completed) HU (Completed) SE (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-005425-11 Sponsor Protocol Number: 3144A2-3003/B1891003 Start Date*: 2009-01-14
    Sponsor Name:Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426 USA
    Full Title: A Phase 2 Randomized Open Label Study of Neratinib versus Lapatinib plus Capecitabine for the Treatment of ErbB-2 Positive Locally Advanced or Metastatic Breast Cancer
    Medical condition: Locally advanced or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) SI (Completed) BE (Completed) DE (Completed) ES (Completed) CZ (Completed) IT (Prematurely Ended) GR (Completed) FR (Completed) AT (Completed) GB (Completed) BG (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-017959-98 Sponsor Protocol Number: OZR-2009-26 Start Date*: 2010-03-25
    Sponsor Name:Rotterdam Eye Hospital
    Full Title: Early treatment of patients with central serous retinopathy: A randomized controlled trial
    Medical condition: central serous retinopathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-000723-94 Sponsor Protocol Number: LP101-CL-201 Start Date*: 2016-08-17
    Sponsor Name:Lyric Pharmaceuticals, Inc.
    Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Comparator-Controlled Study of the Efficacy, Safety, and Pharmacokinetics of Intravenous Ulimorelin (LP101) in Patients with Enteral Feeding Intole...
    Medical condition: Enteral Feeding Intolerance
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004861 10074293 Enteral feeding intolerance LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-001178-20 Sponsor Protocol Number: IM103-307,SMR-2729 Start Date*: 2013-10-29
    Sponsor Name:Uppsala University Hospital, MHT, Department of Nephrology
    Full Title: Cardiovascular (CV) risk prediction and CV biomarkers in renal transplant recipients treated with belatacept compared to calcineurin inhibitors (CNI). Open randomized 12 month study.
    Medical condition: Prophylaxis of graft rejection in adults who have received a renal transplant
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004865 10050436 Prophylaxis against renal transplant rejection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-003330-32 Sponsor Protocol Number: GO28754 Start Date*: 2014-04-17
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF MPDL3280A IN PATIENTS WITH PD L1-POSITIVE LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
    Medical condition: PD-L1-POSITIVE LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed) IT (Completed) BE (Completed) DE (Completed) GB (Completed) NL (Completed) FR (Completed) ES (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2010-020414-28 Sponsor Protocol Number: AP24534-10-201 Start Date*: 2011-02-21
    Sponsor Name:ARIAD Pharmaceuticals, Inc.
    Full Title: A Pivotal Phase 2 Trial of Ponatinib (AP24534) in Patients with Refractory Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia
    Medical condition: Patients with Refractory Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024329 Leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) DE (Completed) FR (Completed) BE (Completed) NL (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-001974-10 Sponsor Protocol Number: CA184-029 Start Date*: 2009-03-13
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Adjuvant immunotherapy with anti-CTLA-4 monoclonal antibody (ipilimumab) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, doubleblind Phase 3 trial of the EORT...
    Medical condition: High Risk Stage III melanoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) IT (Completed) SE (Completed) FI (Completed) CZ (Completed) DK (Completed) DE (Completed) ES (Completed) FR (Completed) AT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2017-000630-57 Sponsor Protocol Number: 20150308 Start Date*: 2017-08-08
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 2a Randomized Double-blind Placebo Controlled Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention.
    Medical condition: Migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10058734 Migraine prophylaxis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) DK (Completed) SE (Completed) FI (Completed) DE (Completed) AT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2017-004005-40 Sponsor Protocol Number: NL63552.000.17 Start Date*: 2018-02-15
    Sponsor Name:Radboud university medical center
    Full Title: Controlled Human Malaria Infection study to assess gametocytaemia and mosquito transmissibility in participants challenged with Plasmodium falciparum by sporozoite challenge to establish a model fo...
    Medical condition: Plasmodium falciparum malaria
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10064864 Malaria antibody positive LLT
    20.0 100000004862 10016171 Falciparum malaria LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-000318-24 Sponsor Protocol Number: RH-ITA-006 Start Date*: 2016-08-30
    Sponsor Name:Dept. of Intensive Care 4131, Copenhagen University Hospital Rigshospitalet
    Full Title: Stress Ulcer Prophylaxis in the Intensive Care Unit
    Medical condition: Prophylaxis of stress related gastrointestinal bleeding among critically ill patients in the intensive care unit.
    Disease: Version SOC Term Classification Code Term Level
    19.1 10042613 - Surgical and medical procedures 10022519 Intensive care PT
    19.1 100000004856 10071910 Upper gastrointestinal bleeding LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) FI (Completed) NO (Completed) NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 1376  1377  1378  1379  1380  1381  1382  1383  1384  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jul 01 09:26:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA